Santhera fully divests rare eye disease drug Raxone to Chiesi

Santhera Pharmaceuticals announced the complete worldwide divestment of Raxone (idebenone) to Chiesi Farmaceutici.

Jul 31, 2023 - 20:00

Santhera fully divests rare eye disease drug Raxone to Chiesi

Santhera Pharmaceuticals announced the complete worldwide divestment of Raxone (idebenone) to Chiesi Farmaceutici.

Read the original article

Tags:

Previous Article

Searchlight licenses Mithra’s menopause drug Donesta for Canadian market

Multicyclic molecular wheels with polymer potential

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: Pharmalittle: EMA urges revoking authorization for Novartis sickle cell drug; U.K. tries to placate pharma execs

STAT+: Pharmalittle: EMA urges revoking authorization f...

May 27, 2023

LifeArc invests nearly $10m in Crick Institute’s Africa Scheme

LifeArc invests nearly $10m in Crick Institute’s Africa...

Aug 14, 2023

STAT+: Pharmalittle: Novartis R&D hub’s name change reflects strategy shift; Lilly’s Mounjaro backed by U.K. watchdog

STAT+: Pharmalittle: Novartis R&D hub’s name change ref...

Sep 8, 2023